NMTC News and Press, NeuroOne Medical Technologies Corporation From 03/28/22

Gainers: DatChat (DATS) +82%. Hycroft Mining Holding Corporation (HYMC) +66%. Plantronics (POLY) +50%. Kaixin Auto (KXIN) +31%. AMC Entertainment Holdings (AMC) +25%. TC Biopharm (TCBP) +23%. Creative Medical Technology (CELZ) +21%. Immunome (IMNM) +21%. Chi...

Gainers: ORIC Pharmaceuticals (ORIC) +19%. Aptorum (APM) +16%. STAAR Surgical (STAA) +16%. Creative Medical Technology (CELZ) +13%. Tempest Therapeutics (TPST) +11%. Losers: NeuroOne Medical Technologies (NMTC) -48%. Clever Leaves (CLVR) -26%. Capricor ...

NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EDEN PRAIRIE, Minn. , March 4, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focus...

NeuroOne to Present its Game-Changing Neuroscientific Technology at the Oppenheimer 32nd Annual Healthcare Conference and 34th Annual ROTH Conference PR Newswire EDEN PRAIRIE, Minn. , March 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ...

NeuroOne® Releases Successful Completion of Long-Term Stimulation Tests for its Novel Thin Film Platform Electrode Technology Successful completion of 5-year stimulation test data presents potential opportunity for long-term applications for Parkinson's disease, epilepsy, s...

NeuroOne Medical Technologies Corporation (NMTC) Q1 2022 Results Conference Call February 14, 2022 4:30 PM ET Company Participants Dave Rosa - Chief Executive Officer Ron Mcclurg - Chief Financial Officer Conference Call Participants Alex Knopick - Craig-Hallum Capital Ben Haynor - Alliance G...

NeuroOne Medical Technologies press release (NASDAQ:NMTC): FQ1 Net loss of $2.8M. Revenue of $0.04M (-55.6% Y/Y). For further details see: NeuroOne Medical Technologies net loss of $2.8M, revenue of $0.04M

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update PR Newswire EDEN PRAIRIE, Minn. , Feb. 14, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical techn...

NeuroOne Medical Technologies (NMTC +11.4%) is trading higher after announcing that the company successfully concluded initial pre-clinical testing designed to assess the long-term recording capabilities of its platform thin film electrode technology. NeuroOne (NASDAQ:NMTC) is advancing the m...

NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology Successful results of 5-year test data opens potential opportunity for long-term recording applications for Parkinson's disease...